Oncology

News

Anne Wojcicki, CEO and co-founder of 23andMe

23andMe board rebuffs CEO plan to take the firm private

A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.

News

GSK raises forecasts for 2024, but shares slide

GSK posted a healthy 13% increase in second-quarter sales this morning and raised its forecasts for the year on the back of gains for its cancer and HIV drugs, beating market expectations.

News

Close-up image of a melanoma on the skin

BioNTech cancer vaccine hits the spot in melanoma

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.

News

Boehringer buys oncology player Nerio in $1.3bn deal

Boehringer Ingelheim has bought Nerio Therapeutics, saying that it is adding a programme that – while still in preclinical development – could be a "centrepiece" of its immuno-oncology pipe

News

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

FDA reviewers were so frustrated by AstraZeneca's application for Imfinzi as a treatment before and after surgery for resectable non-small cell lung cancer (NSCLC) that they voted for a ret

News

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

23andMe board rebuffs CEO plan to take the firm private

GSK raises forecasts for 2024, but shares slide

BioNTech cancer vaccine hits the spot in melanoma

Boehringer buys oncology player Nerio in $1.3bn deal

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

Ipsen builds again, licensing Day One glioma drug

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

Oncology

Editor's Picks